Clinical safety of treatment with Zileuton, 5-Lox inhibitor, during acute inflammatory reaction in Nile Tilapia (Oreochromis niloticus) / Segurança clínica do tratamento com Zileuton, inibidor 5-Lox, durante reação inflamatória aguda em Tilápia do Nilo (Oreochromis niloticus)

Zileuton is an inhibitor of the 5-lipoxygenase enzyme that transforms essential fatty acid (EFA) substrates into leukotrienes (LTB4, LTC4, LTD4 and LTE4), but little is known about the use of this drug in teleost fish. Therefore, the objective of this study was to evaluate the clinical safety of treatments with 2,25 mg and 4,50 mg of zileuton/Kg-1 (bodyweight), administered orally in the diet, through biochemical and hematological analysis during the acute inflammatory reaction in Nile tilapia (Oreochromis niloticus), induced by Aeromonas hydrophila bacterins. The study used eighty tilapias, conditioned in 20 tanks (n=4), constituting the following treatments: T0 (control), T1 (2,25 mg zileuton) and T2 (4,50 mg zileuton), being sampled eight animals per treatment in three periods: 6, 24 and 48 hours post-inoculation, and a 10th group consisting of fish without any type of stimulus to obtain the reference values. In order to evaluate and determine the blood count and serum biochemical, it was necessary to collect blood samples. The hematology results of the tilapia treated with zileuton did not reveal alterations between tilapia subjected to different treatments and control fish (T0). The liver cytotoxicity analysis of tilapias treated with zileuton did not reveal significant (p≥0,05) alterations in AST and ALT serum enzymatic activity. The study of tilapia blood total protein showed decrease in the T1 group at 48 HPI. As the treatment time progressed, the results indicated decrease in the serum albumin levels for T2 group at 24 HPI. The determination of serum biochemichal of creatinine, cholesterol, triglycerides, and glucose did not differ statistically between treatments. The results observed in the hematological and biochemical analyzes allows to conclude that zileuton administered orally, at doses of 2,25 and 4,50 mg/Kg-1 (body weight) demonstrated to be clinically safe.(AU)

Safety of oral doxycycline treatment in Nile tilapia, Oreochromis niloticus / Segurança do tratamento oral com doxiciclina em tilapia do Nilo, Oreochromis niloticus

This study aimed to evaluate the clinical safety of doxycycline treatment (Sandoz Pharmacetical Industry from Brazil Ltd.), administered orally incorporated into the feed of Nile tilapia, Oreochromis niloticus. For this purpose, 75 Nile tilapia (±300g) from the same spawning were randomly distributed in 15 tanks (n=5), containing 100 L of water each, supplied with running water free from chlorine, to establish the following treatments: TO (Control - not treated with doxycycline); T1, T2, T3 and T4 (treated with 10, 20, 40 and 80mg of doxycycline/kg of body weight, respectively), in which 5 animals per treatment were sampled in 3 periods: 2, 4 and 8 days post-treatment (DPT). Blood samples were collected for hemogram determination and serum biochemical evaluation, as well as spleen, liver and kidneys (cranial and caudal) for somatic and histopathological evaluation. The results showed no significant difference among treatments in the serum values of creatinine, total protein, cholesterol, triglycerides, globulin, glycemia and alkaline phosphatase enzyme activity. However, serum levels of AST (aspartate aminotransferase) were significantly higher (P<0.05) in animals treated with 80 mg of doxycycline in the longest period of treatment (8 days). In the hematological evaluation of tilapia treated with doxycycline, no significant changes (P>0.05) were observed in erythrocyte counts, hematocrit, MCV, HCM and CHCM values. Doxycycline-treated tilapia did not present significant difference in the somatic analysis of spleen, liver and kidney when compared to control group. Therefore, the results demonstrated the clinical safety of oral treatment with doxycycline at doses of 10, 20, 40 and 80 mg/kg of b.w., although transient changes in liver functionality were observed after eight days of treatment with the dose of 80mg/kg.

Este estudo teve por objetivo avaliar a segurança clínica do tratamento com doxiciclina (Sandoz do Brasil Indústria Farmacêutica Ltda.), administrada via oral incorporada à ração em tilápias do Nilo, Oreochromis niloticus. Para tal, foram utilizadas 75 tilápias no Nilo (±300g) oriundas da mesma desova foram distribuídas aleatoriamente em 15 tanques (n=5), contendo 100 L de água cada, abastecidos com água corrente desprovida de cloro, para constituir os seguintes tratamentos: TO (Controle - não tratado com doxiciclina); T1, T2, T3 e T4 (tratados com 10, 20, 40 e 80mg de doxiciclina/kg de p.v., respectivamente. 5 animais por tratamento foram amostrados em 3 períodos: 2, 4 e 8 dias pós-tratamento (DPT). Foram coletadas amostras de sangue para determinação do hemograma e avaliação do bioquímico sérico, além de órgãos como baço, fígado e rins (cranial e caudal) para avaliação somática e histopatológica. Os resultados não mostraram diferença significativa entre os tratamentos nos valores séricos de creatinina, proteína total, colesterol, triglicerídeos, globulina, glicemia e atividade da enzima fosfatase alcalina. No entanto, os níveis séricos de AST (aspartato aminotransferase) foram significativamente maiores (P<0,05) nos animais tratados com 80 mg de doxiciclina no período mais longo de tratamento (8 dias). Na avaliação hematológica de tilápias tratadas com doxiciclina, não foram observadas alterações significativas (P>0,05) nas contagens de eritrocitos, valores de hematocrito, VCM, HCM e CHCM. Tilápias tratadas com doxiciclina não apresentaram diferença significativa na análise somática do baço, fígado e rim quando comparadas aos animais do grupo controle. Portanto, os resultados demonstraram a segurança clínica do tratamento oral com doxiciclina nas doses de 10, 20, 40 e 80 mg/kg de peso corporal, embora alterações transitórias na funcionalidade hepática tenham sido observadas após oito dias de tratamento com a dose de 80mg/kg.